Comprehensive Analysis Based on the Cancer Immunotherapy and Immune Activation of Gastric Cancer Patients

Figure 6

(a) Immunotherapy evaluation of CTLA4 negative and PD1 negative patients between low- and high-risk groups. (b) Immunotherapy evaluation of CTLA4 negative and PD1 positive patients between low-and high-risk groups. (c) Immunotherapy evaluation of CTLA4 positive and PD1 negative patients between low- and high-risk groups. (d) Immunotherapy evaluation of CTLA4 positive and PD1 positive patients between low-and high-risk groups.

(a)

(b)

(c)

(d)